Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Gujarat Kidney
Quarter-by-quarter operating performance
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Sales + | 9.41 | 11.79 | 9.78 | 15.26 | 12.93 | 23.25 | 30.58 |
| Expenses + | 4.55 | 7.19 | 7.17 | 6.64 | 7.81 | 16.35 | 24.28 |
| Operating Profit | 4.86 | 4.60 | 2.61 | 8.62 | 5.12 | 6.90 | 6.30 |
| OPM % | 51.65% | 39.02% | 26.69% | 56.49% | 39.60% | 29.68% | 20.60% |
| Other Income + | 0.04 | 0.05 | 0.05 | 0.01 | 0.09 | 0.06 | 0.71 |
| Interest | 0.16 | 0.17 | 0.16 | 0.18 | 0.28 | 0.60 | 0.82 |
| Depreciation | 0.74 | 0.88 | 0.90 | 0.96 | 0.90 | 1.33 | 1.51 |
| Profit before tax | 4.00 | 3.60 | 1.60 | 7.49 | 4.03 | 5.03 | 4.68 |
| Tax % | 26.25% | 29.72% | 16.88% | 27.77% | 28.54% | 26.44% | -2.99% |
| Net Profit + | 2.96 | 2.53 | 1.34 | 5.40 | 2.88 | 3.70 | 4.82 |
| EPS in Rs | 18.39 | 15.53 | 0.23 | 0.85 | 0.47 | 0.37 | 0.64 |
Financials of Gujarat Kidney
Annual income statement trend
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Sales + | 0 | 5 | 40 | 82 |
| Expenses + | 0 | 3 | 24 | 55 |
| Operating Profit | -0 | 2 | 17 | 27 |
| OPM % | 41% | 41% | 33% | |
| Other Income + | 0 | 1 | 0 | 1 |
| Interest | 0 | 0 | 1 | 2 |
| Depreciation | 0 | 0 | 3 | 5 |
| Profit before tax | -0 | 2 | 13 | 21 |
| Tax % | 0% | 25% | 26% | 21% |
| Net Profit + | -0 | 2 | 10 | 17 |
| EPS in Rs | -0.50 | 85.50 | 1.66 | 1.97 |
| Dividend Payout % | 0% | 0% | 0% | 0% |
Financials of Gujarat Kidney
Capital structure and asset base
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Equity Capital | 0.20 | 0.20 | 11 | 16 |
| Reserves | 0 | 11 | 15 | 237 |
| Borrowings + | 0 | 6 | 8 | 29 |
| Other Liabilities + | 4 | 4 | 21 | 16 |
| Total Liabilities | 4 | 21 | 55 | 298 |
| Fixed Assets + | 0 | 14 | 31 | 129 |
| CWIP | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 |
| Other Assets + | 4 | 7 | 24 | 169 |
| Total Assets | 4 | 21 | 55 | 298 |
Financials of Gujarat Kidney
Operating, investing and financing cash movement
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Cash from Operating Activity + | 0 | 1 | 14 | |
| Cash from Investing Activity + | 0 | 0 | -18 | |
| Cash from Financing Activity + | 0 | -0 | 6 | |
| Net Cash Flow | 0 | 1 | 2 | |
| Free Cash Flow | 0 | 2 | -5 | |
| CFO/OP | 0% | 70% | 99% |
Financials of Gujarat Kidney
Working capital efficiency and return ratios
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Debtor Days | 321 | 138 | 172 | |
| Inventory Days | 82 | |||
| Days Payable | 339 | |||
| Cash Conversion Cycle | 321 | 138 | -84 | |
| Working Capital Days | 100 | -24 | 91 | |
| ROCE % | 19% | 52% | 14% |
Volume-led growth with inpatient (IP) volumes up 39% and outpatient (OP) volumes up 26% year-on-year. Key concall takeaways from Manipal Health Enterprises…
IHH plans to increase its stake in Fortis to over 50% within 3-5 years, supporting long-term strategic growth. Key concall takeaways from Fortis Healthcare…
East India currently 6%, with limited investment so far; future investments may increase contribution. Key concall takeaways from Metropolis Healthcare Ltd's…
IP volume growth for established units guided at roughly 7% to 8%. Key concall takeaways from Apollo Hospitals Enterprise Ltd's Q1 FY27 earnings call — and how…